Product Description
Azimilide is an investigational class III agent with electrophysiological effects on the repolarization phase of the cardiac action potential that are similar to amiodarone. (Sourced from: https://www.ahajournals.org/doi/10.1161/01.cir.0000151357.36405.72)
Mechanisms of Action: Potassium Channel Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Atrial Fibrillation|Ventricular Fibrillation|Tachycardia, Ventricular|Other|Cardiac Arrhythmias
Phase 2: Heart Failure
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2011-004376-11 | P3 |
Terminated |
Unknown |
2014-11-15 |
2022-03-13 |
Treatments |
|
| SHIELD-2 | P3 |
Terminated |
Cardiac Arrhythmias |
2013-05-01 |
2019-03-19 |
Treatments |
|
| NCT00752596 | P2 |
Completed |
Heart Failure |
2006-07-01 |
2019-03-18 |
Treatments |
|
| NCT00318838 | P1 |
Completed |
Healthy Volunteers |
2006-05-01 |
2019-03-21 |
Treatments |
|
| NCT00751738 | P3 |
Completed |
Other |
2005-10-01 |
2019-03-18 |
Treatments |
|
| NCT00035490 | P3 |
Completed |
Ventricular Fibrillation|Tachycardia, Ventricular |
2004-04-01 |
2019-03-21 |
||
| NCT00035464 | P3 |
Completed |
Atrial Fibrillation |
2004-01-01 |
2019-03-21 |
Treatments |
|
| NCT00035477 | P3 |
Completed |
Atrial Fibrillation |
2003-10-01 |
2019-03-21 |
||
| NCT00035451 | P3 |
Completed |
Atrial Fibrillation |
2003-06-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|